Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

References

• Chiarie R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinase in lung cancer. Cell. 2007;131:1190–1203.
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275–4283.
   PubMed Web of Science ®Google Scholar
• Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from non smokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723–1733.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small- cell lung cancer who harbour EML4-ALK. J Clin Oncol. 2009;27:4247–4253.
   PubMed Web of Science ®Google Scholar
• Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22:508–515.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859.
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii2739.
   Web of Science ®Google Scholar
• Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32:3673–3679.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Doebele RC. Targeting ALK-positive lung cancer –early succes and future challanges. Nat Rev Clin Oncol. 2012;9:268–277.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31:1105–1111.
   PubMed Web of Science ®Google Scholar
• Solomon B, Wilner KD, Shaw AT, et al. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther. 2014;95:15–23.
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Pnas. 2004;101:13306–13311.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Varella-Garcia ML, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005;23:5007–5018.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–655.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Bemis L, Varella-Garcia ML, et al. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 2006;354:2619–2621.
   PubMed Web of Science ®Google Scholar
• Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Pnas. 2008;105:19893–19897.
   PubMed Web of Science ®Google Scholar
• McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68:3389–3395.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–1703.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in LAK-positive lung cancer. N Engl J Med. 2014;371:2167–2177.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance t crizotinib in ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2014;18:1472–1482.
   Web of Science ®Google Scholar
• Marsilje TH, Pei W, Chen B, et al. Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine(LDK378) Currently in Phase 1 and Phase 2 Clinical Trials. J Med Chem. 2013;56:5675–5690.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–1197.
   PubMed Web of Science ®Google Scholar
• Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: Ceritnib for the treatment of metastatic Anaplastic-Lymphoma Kinase-Positive non-small cell lung cancer. Clin Cancer Res. 2015;21:2436–2439.
   PubMed Web of Science ®Google Scholar
• Felip E, Orlov S, Park K, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. (suppl; abstr 8060)
   Web of Science ®Google Scholar
• Camidge DR, Pao W, Sequist L. Acquired resistance to TKIs in solid tumors: learning from lung cancer. Nat Rev Clin Oncol. 2014;11:473–481.
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012;4:120ra17.
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734–1739.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010;70:10038–10043.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinae inhibitors. Cancer Res. 2011;71:6051–6060.
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okabe T, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res. 2012;18:6219–6226.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Sh OU, Logan J, et al. The central nervous system as a sanctuaty site in ALK-positive non-small cell lung cancer. J Thor Oncol. 2013;8:1570–1573.
   PubMed Web of Science ®Google Scholar
• Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther. 2012;13:1376–1383.
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443e445.
   Google Scholar
• Galkin AV, Melnick JS, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Pnas. 2007;104:270–275.
   PubMed Web of Science ®Google Scholar
• Fibroulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4:662–673.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Khuri FR. Second generation ALK inhibitors: filling the non “MET” gap. Cancer Discov. 2014;4:634–636.
   PubMed Web of Science ®Google Scholar
• Nishio M, Murakami H, Horiike A, et al. Phase I study of ceritinib (LDK378) in Japanese patients with advanced, Anaplastic Lymphoma Kinase-rearranged NSCLC or other tumors. J Thor Oncol. 2015;10:1058–1066.
   PubMed Web of Science ®Google Scholar
• Felip E, Kim DW, Mehra R. Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)- rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of the ASCEND-1. Ann Oncol. 2014;25(suppl 4):iv26iv470.
   Google Scholar
• Mok T, Spigel D, Felip E, et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2015;33. (suppl; abstr 8059)
   Web of Science ®Google Scholar
• Shaw AT, Mehra R, Tan DSW, et al. Evaluation of ceritinib-treated patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases. Ann Oncol. 2014;25(suppl 4):iv26iv470.
   Google Scholar
• Mehra R, Camidge DR, Sharma S, et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. J Clin Oncol. 2012;30(suppl): abstr 3007.
   Google Scholar
• Toyokawa G, Inamasu E, Shimamatsu S, et al. Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. J Thorac Oncol. 2015;10:e55e57.
   Web of Science ®Google Scholar
• Cameron L, Solomon B. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. Drugs. 2015;75:1059–1070.
   PubMed Web of Science ®Google Scholar
• Ou S-H I, Ahn JS, De Petris L, et al. Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open label, single arm, global, phase 2 study (NP28673). J Clin Oncol. 2015;33. (suppl; abstr 8008).
   PubMed Web of Science ®Google Scholar
• Seto T, Katsuyuki K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1/2 study. Lancet Oncol. 2013;14:590–598.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Dingemans A, Ou I, et al. Updated efficacy and safety results from a global phase 2, open label, single arm study (NP28673) of alectinib in crizotinib-refractory ALK + non-small cell lung cancer (NSCLC). Brit J Cancer. 2015;51(S3):S635.
   Google Scholar
• Camidge DR, Bazhenova L, Salgia R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl): abs. 8062.
   PubMed Web of Science ®Google Scholar
• Ou S, Gadgeel S, Chiappori A, et al. Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028). Eur J Cancer. 2013;49(suppl3):s19.
   Google Scholar
• Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression free survival, and overall survival with targeted and standard therapies in adanced non-small cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015;33:1008–1014.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim TM, Kim DW, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearanged lung cancer. J Thor Oncol. 2013;8:415–422.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tan DS, De Pas T, et al. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res. 2015;21:2745–2752.
   PubMed Web of Science ®Google Scholar